Biomarker Clinical Phase Outsourcing Services Market Report 2026

The biomarker clinical phase outsourcing services market size has grown exponentially in recent years. It will grow from $11.91 billion in 2025 to $14.62 billion in 2026 at a compound annual growth rate (CAGR) of 22.7%. The growth in the historic period can be attributed to increasing complexity of clinical trial designs, rising oncology clinical research activity, growth of biomarker-driven drug development, expansion of translational research programs, increasing collaboration with specialized service providers.

The biomarker clinical phase outsourcing services market size is expected to see exponential growth in the next few years. It will grow to $30.4 billion in 2030 at a compound annual growth rate (CAGR) of 20.1%. The growth in the forecast period can be attributed to increasing demand for personalized medicine trials, rising adoption of ai-driven biomarker analytics, expansion of multi-biomarker clinical studies, growing investments in precision oncology, increasing regulatory emphasis on biomarker validation. Major trends in the forecast period include increasing outsourcing of biomarker clinical trial activities, rising use of predictive and prognostic biomarkers, growing integration of omics-based biomarker analysis, expansion of companion diagnostics development, enhanced focus on precision medicine trials.

The increase in clinical trials is anticipated to drive the growth of the biomarker clinical phase outsourcing services market in the coming years. Clinical trials are systematic research studies involving human participants to assess the safety and efficacy of new medical treatments, interventions, or diagnostic methods. The expansion of clinical trials is supported by advances in medical research, a growing burden of chronic diseases, higher levels of funding from government and private organizations, and rising demand for novel therapies and treatment options. Outsourcing service providers typically possess specialized expertise in biomarker identification, validation, and analysis, which helps improve the accuracy, quality, and reliability of biomarker data generated during clinical trials. For example, in November 2025, the National Library of Medicine, a US-based biomedical library, reported that ClinicalTrials.gov listed 558,242 studies conducted across all 51 US states and in 224 countries and territories. Consequently, the growing number of clinical trials is expected to support the continued expansion of the biomarker clinical phase outsourcing services market.

Leading companies in biomarker clinical phase outsourcing services are emphasizing advancements in high-throughput flow cytometry and ELISpot testing to strengthen their competitive position in the market. High-throughput flow cytometry and ELISpot assays are widely applied in biomarker analysis, enabling fast and accurate evaluation of immune responses and cellular markers. For example, in May 2024, KCAS Bio, a U.S.-based bioanalytical CRO providing GLP/GCP-compliant biomarker and immune-monitoring services, entered into a global spectral flow cytometry alliance with Crux Biolabs, an Australian CRO with expertise in ELISpot and flow cytometry assays. As part of this collaboration, KCAS Bio deployed harmonized spectral cytometers at Crux Biolabs’ facilities, enabling clients to access high-throughput, multiparametric flow cytometry across the U.S., Europe, and Australia. This partnership enhances KCAS Bio’s biomarker development and immune-monitoring capabilities by delivering rapid and accurate cellular biomarker assessment in clinical trials, helping clients produce high-quality data that supports regulatory submissions and speeds up drug development.

In March 2023, SSI Strategy, a US-based life sciences consulting services firm, partnered with Koneksa to strengthen patient monitoring in clinical research. This collaboration is intended to enhance patient tracking and simplify research workflows, allowing pharmaceutical and biotechnology companies to obtain deeper insights and speed up the development of new therapies. Together, they concentrate on expanding the use of real-world data and remote monitoring technologies to enable more efficient and patient-focused clinical studies. Koneksa is a US-based health technology company that specializes in digital biomarkers and clinical research.

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Evotec SE, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Metabolon Inc., Caprion Proteomics Inc., Intertek Group plc, Bioclinica Inc., GenScript Biotech Corporation, Selvita S.A.

North America was the largest region in the biomarker clinical phase outsourcing services market in 2025. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biomarker clinical phase outsourcing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biomarker clinical phase outsourcing services market by increasing costs of imported analytical instruments, sequencing platforms, reagents, and data management systems used in biomarker validation and testing. North America and Europe are most affected due to reliance on imported high-throughput technologies, while Asia-Pacific faces higher costs for advanced diagnostic tools. These tariffs are raising trial execution costs and extending study timelines. However, they are also encouraging local laboratory expansion, regional technology partnerships, and domestic development of biomarker analysis capabilities.

The biomarker clinical phase outsourcing services market research report is one of a series of new reports that provides biomarker clinical phase outsourcing services market statistics, including biomarker clinical phase outsourcing services industry global market size, regional shares, competitors with a biomarker clinical phase outsourcing services market share, detailed biomarker clinical phase outsourcing services market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker clinical phase outsourcing services industry. This biomarker clinical phase outsourcing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biomarker clinical phase outsourcing services involve engaging specialized firms or organizations to manage different components of biomarker-related clinical trials. Biomarkers are quantifiable biological indicators that reflect physiological or pathological processes and are commonly used in medical research and clinical studies to evaluate the efficacy or safety of a drug or therapeutic intervention.

The primary categories of biomarker clinical phase outsourcing services include surrogate endpoints, predictive biomarkers, prognostic biomarkers, safety biomarkers, and others. Surrogate endpoints are biomarkers designed to replace a clinical endpoint, and outsourcing services leverage these endpoints to optimize clinical trials by offering early signals of effectiveness, shortening trial timelines, and potentially speeding up regulatory approvals. Service offerings such as biomarker validation, biomarker testing services, and biomarker sample analysis are applied across therapeutic areas including oncology, neurology, cardiology, autoimmune disorders, and others. The key end users of these services are pharmaceutical companies, biotechnology firms, and academic and research organizations.

The biomarker clinical phase outsourcing services market includes revenues earned by entities by consulting services, diagnostic tests, clinical trial design, and biomarker sample analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.